Plasminogen activating substances

Mecfianism of Action A systemic hemostatic that acts as an antifibrinolytic and an-tihemorrhagicby inhibitingthe activation of plasminogen activator substances. Therapeutic Effect Prevents formation of fibrin dots. 

Yang Tissue Plasminogen Activator (TPA) springs forth. Variously shuffled domains allow it to bind to several substances, including fibrin. 

Urokinase is an endogenous plasminogen activator that occurs in different organs. Urokinase used therapeutically is obtained from human cultured kidney cells. Circulating antibodies are not expected. The substance is more expensive than streptokinase and also does not depend on fibrin in its action. 

Alteplase is a recombinant tissue plasminogen activator (rt-PA). As a result of its production in eukaryotic Chinese hamster ovary (CHO) cells, carbohydrate residues are present as in the native substance. At the therapeutically used dosage, alteplase loses its fibrin dependence and thus also activates circulating plasminogen. In fresh myocardial infarctions, alteplase appears to produce better results than does streptokinase. 

---